Protocol Ledger

NCT03608397 · Phase III · COMPLETED

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

Interventional Phase III clinical trial protocol NCT03608397 sponsored by Revance Therapeutics in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-06-20 Enrollment: 301 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03608397
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)301 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03608397
Protocol FieldVerified Registry Value
NCT IdentifierNCT03608397
Consolidated Lead SponsorRevance Therapeutics
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment301 participants (ACTUAL)
Registered Start Date2018-06-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI